Perrigo Has First US Approval For OTC Omeprazole Mini-Capsule
Executive Summary
Capsule is 70% smaller than tablets of omeprazole currently available in Prilosec OTC and generic equivalents, including formulations Perrigo provides for its private label and store brand customers.
You may also be interested in...
Perrigo’s First National Brand, Nasonex OTC Switch, Will Have Familiar Buzz In Advertising
Firm to promote Nasonex 24HR Allergy nasal spray with cartoon bee familiar with brand’s marketing as an Rx product. It doesn't anticipate receiving OTC market exclusivity along with approval of first OTC mometasone furoate product in US.
Perrigo Debuts On US National Brand Stage With OTC Switch Approval For Nasonex 24HR Allergy
Nasonex 24HR Allergy also will be first OTC mometasone furoate product available in US. It will compete in OTC intranasal corticosteroids category already led by other brands switched from Rx to nonprescription over past eight years.
Perrigo Prioritizes Innovating First After Following OTC Brands To Market
Perrigo’s "national brand better" approach includes adding "better" value to generic equivalents that branded aren't offering, says President and CEO Murray Kessler. Prevacid 24 HR acquisition puts Perrigo at top of 15-mg lansoprazole PPI brand sales as well as in the generics market.